JANX (Janux Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by JANX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | David Alan Campbell | President and CEO | G | — | — |
| 2026-07-10 | David Alan Campbell | President and CEO | M | — | — |
| 2026-06-12 | ERIC DOBMEIER | Director | A | — | — |
| 2026-06-12 | Jake Simson | Director | A | — | — |
| 2026-06-12 | Winston Kung | Director | A | — | — |
| 2026-06-12 | Natasha Hernday | Director | A | — | — |
| 2026-06-12 | Ronald W Barrett | Director | A | — | — |
| 2026-06-12 | VICKIE L CAPPS | Director | A | — | — |
| 2026-06-12 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2026-06-04 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | Sell | — | — |
| 2026-05-13 | Maria Dobek | Vice President, Accounting | Sell | — | — |
| 2026-02-04 | William Go | Chief Medical Officer | A | — | — |
| 2026-01-02 | Charles M. Winter | Chief Technical Officer | MIXED | — | — |
| 2026-01-02 | Zachariah McIver | Chief Medical Officer | MIXED | — | — |
| 2026-01-02 | Maria Dobek | Vice President, Accounting | MIXED | — | — |
| 2026-01-02 | Thomas DiRaimondo | Chief Scientific Officer | MIXED | — | — |
| 2026-01-02 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | A | — | — |
| 2026-01-02 | David Alan Campbell | President and CEO | MIXED | — | — |
| 2026-01-02 | Andrew Hollman Meyer | Chief Business Officer | Sell | — | — |
| 2025-12-03 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-11-14 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-10-30 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-06-13 | Alana B. McNulty | Director | A | — | — |
| 2025-06-13 | VICKIE L CAPPS | Director | A | — | — |
| 2025-06-13 | ERIC DOBMEIER | Director | A | — | — |
| 2025-06-13 | Natasha Hernday | Director | A | — | — |
| 2025-06-13 | Ronald W Barrett | Director | A | — | — |
| 2025-06-13 | Jake Simson | Director | A | — | — |
| 2025-06-13 | Winston Kung | Director | A | — | — |
| 2025-06-13 | Sheila Gujrathi | Director | A | — | — |
| 2025-06-13 | RA Capital Nexus Fund II, L.P. | Director | A | — | — |
| 2025-06-04 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | A | — | — |
| 2025-05-02 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-04-23 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-03-07 | Rajeev M. Shah | Director | Buy | — | — |
| 2025-03-05 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-02-05 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-01-08 | David Alan Campbell | President and CEO | Sell | — | — |
| 2025-01-03 | Thomas DiRaimondo | Chief Scientific Officer | A | — | — |
| 2025-01-03 | David Alan Campbell | President and CEO | A | — | — |
| 2025-01-03 | Maria Dobek | Vice President, Accounting | A | — | — |
| 2025-01-03 | Byron Robinson | Chief Strategy Officer | A | — | — |
| 2025-01-03 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | — |
| 2025-01-03 | Zachariah McIver | Chief Medical Officer | A | — | — |
| 2025-01-03 | Charles M. Winter | Chief Technical Officer | A | — | — |
| 2024-12-27 | David Alan Campbell | President and CEO | Sell | — | — |
| 2024-12-20 | Andrew Hollman Meyer | Chief Business Officer | M | — | — |
| 2024-12-03 | David Alan Campbell | President and CEO | Sell | — | — |
| 2024-11-27 | David Alan Campbell | President and CEO | Sell | — | — |
| 2024-11-07 | Sheila Gujrathi | Director | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 10,031,081 | — |
| — | 10%+ Owner | 8,237,298 | — |
| — | 10%+ Owner | 6,392,225 | — |
| — | 10%+ Owner | 3,904,889 | — |
| — | 10%+ Owner | 3,443,304 | — |
| — | Director | 2,760,366 | — |
| — | Director | 2,403,566 | — |
| — | Director | 2,295,266 | — |
| — | Director | 1,048,406 | — |
| — | Acting Chief Financial Officer | 808,662 | — |
| — | Director | 582,095 | — |
| — | President and CEO | 264,742 | — |
| — | Director | 231,098 | — |
| — | Director | 231,098 | — |
| — | Chief Scientific Officer | 155,825 | — |
| — | Director | 118,889 | — |
| — | Chief Technical Officer | 106,321 | — |
| — | Chief Business Officer | 83,095 | — |
| — | Director | 79,598 | — |
| — | Chief Corp. & Bus. Dev. Ofcr | 75,941 | — |
| — | Chief Medical Officer | 44,000 | — |
| — | Vice President, Accounting | 32,270 | — |
| — | Chief Strategy Officer | 28,000 | — |
| — | Chief Medical Officer | 23,286 | — |
| — | Director | 15,481 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JANX quote page; the site-wide leaderboard is on the insider transactions hub.